Market revenue in 2020 | USD 7,621.3 million |
Market revenue in 2028 | USD 12,938.0 million |
Growth rate | 6.8% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | Neurodegenerative Diseases |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 42.82% in 2020. Horizon Databook has segmented the Japan central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
Japan is one the major markets for CNS therapeutics in the Asia Pacific region, which can be attributed to the presence of strong local players and well-established healthcare infrastructure. The Japanese government is responsible for the country’s Universal Statutory Health Insurance System (SHIS) fee schedule and provides financial benefits to insurers & service providers.
In April 2018, Kyushu Certified Special Committee for Regenerative Medicine approved for the world’s first stem cell therapy, to treat mild-to-moderate Alzheimer’s disease. This innovative therapy has been developed by Korean biotech company Nature Cell and Biostar Stem Cell Research Institute.
Approval of novel therapies and increasing R&D activities to develop effective treatment for neurological conditions are factors anticipated to drive the market over the forecast period. According to the Global Cancer Observatory, in 2020, the 5-year prevalence of brain.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into Japan central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account